.Nature Medication, Published online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Perspective calls for introduction of people with MASLD and size of liver results in cardio-- renal-- metabolic trials, when information recommend mechanistically plausible advantages as well as scientific security-- as well as outlines considerations for trial concept and regulatory commendation.